JNJ Press releases 28 March 2018 Big Pharma’s Billion-Dollar Scramble to Invest in Start-ups to Fuel Innovation Read full story
JNJ Press releases 18 March 2018 Helsinn Group announces agreement to acquire worldwide rights to Valchlor®/Ledaga® - an approved and marketed alkylating agent for the topical treatment of mycosis fungoides‐type cutaneous T‐cell lymphoma, a rare type of skin cancer Read full story
